Literature DB >> 26004880

Epidural analgesia in the intensive care unit: An observational series of 121 patients.

Matthieu Jabaudon1, Russell Chabanne2, Achille Sossou3, Pierre-Marie Bertrand4, Sophie Kauffmann2, Christian Chartier5, Renaud Guérin5, Etienne Imhoff2, Lassane Zanre3, François Brénas3, Jean-Etienne Bazin5, Jean-Michel Constantin6.   

Abstract

BACKGROUND: Epidural analgesia (EA) has been more investigated during the perioperative period than in the intensive care unit (ICU) setting. Recent studies support beneficial effects for EA beyond analgesia itself. However, data on feasibility and safety are still lacking in the ICU. Our goal was to assess the feasibility and practice of EA in ICU patients.
METHODS: Multicentre observational study in 3 ICUs over a 10-month period. Goals were to report the incidence of EA-related complications and EA duration. All ICU patients receiving EA were included, whether EA was initiated in the ICU or elsewhere, e.g. in the operating room. Demographics, clinical and biological data were prospectively recorded. Epidural catheter tips were sent to the microbiology laboratory for culture.
RESULTS: One hundred and twenty-one patients were included (mean age 60 years), with mean SOFA and median SAPS II scores of 3.2 and 32, respectively. Reasons for EA initiation included trauma (14%), postoperative pain management after major surgery (42%), and pancreatitis (31%). No EA-related neurologic complication was recorded, and one case of epidural abscess is discussed. No other EA-related infectious complications were observed. Median duration of EA was 11 days. Reasons for EA discontinuation included efficient analgesia without EA (60%) and accidental catheter removal (17%). 22% of epidural catheter cultures were positive for skin flora bacteria.
CONCLUSION: EA seems feasible in the ICU. Its apparent safety should be further validated in larger cohorts, but these preliminary results may stimulate more interest in the assessment of potential benefits associated with EA in the ICU setting.
Copyright © 2015 Société française d’anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Epidural analgesia; Epidural complications; Feasibility; Intensive care unit

Mesh:

Year:  2015        PMID: 26004880     DOI: 10.1016/j.accpm.2014.12.002

Source DB:  PubMed          Journal:  Anaesth Crit Care Pain Med        ISSN: 2352-5568            Impact factor:   4.132


  5 in total

1.  Epidural analgesia in critically ill patients with acute pancreatitis: the multicentre randomised controlled EPIPAN study protocol.

Authors:  Stéphanie Bulyez; Bruno Pereira; Elodie Caumon; Etienne Imhoff; Laurence Roszyk; Lise Bernard; Leo Bühler; Claudia Heidegger; Samir Jaber; Jean-Yves Lefrant; Russell Chabanne; Pierre-Marie Bertrand; Pierre-François Laterre; Philippe Guerci; Pierre-Eric Danin; Etienne Escudier; Achille Sossou; Dominique Morand; Vincent Sapin; Jean-Michel Constantin; Matthieu Jabaudon
Journal:  BMJ Open       Date:  2017-05-29       Impact factor: 2.692

2.  Acute cerebral infarction in a patient with an epidural catheter after left upper lobectomy: a case report.

Authors:  Asuka Kitajima; Yuji Otsuka; Alan Kawarai Lefor; Masamitsu Sanui
Journal:  BMC Anesthesiol       Date:  2019-02-23       Impact factor: 2.217

3.  Effect of Segmental Thoracic Epidural Block on Pancreatitisinduced Organ Dysfunction: A Preliminary Study.

Authors:  Asha Tyagi; Yash Raj Gupta; Shukla Das; Gargi Rai; Arun Gupta
Journal:  Indian J Crit Care Med       Date:  2019-02

4.  Epidural Analgesia for Pain Management in Acute Pancreatitis during Pregnancy and Its Effect on Maternal and Fetal Outcome.

Authors:  Sandeepika Dogra; Pallavi Sharma; Sunil Pandya; Manokanth Madapu; Soumya Jagannath Mahapatra; Ankita Sethi; Nilanchali Singh
Journal:  Obstet Gynecol Int       Date:  2022-09-14

5.  [SBA 2020: Regional anesthesia safety recommendations update].

Authors:  Liana Maria Tôrres de Araújo Azi; Neuber Martins Fonseca; Livia Gurgel Linard
Journal:  Braz J Anesthesiol       Date:  2020-05-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.